These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35678461)

  • 1. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
    Nomah DK; Reyes-Urueña J; Díaz Y; Moreno S; Aceiton J; Bruguera A; Vivanco-Hidalgo RM; Casabona J; Domingo P; Navarro J; Imaz A; Deig E; Navarro G; Llibre JM; Miro JM;
    J Antimicrob Chemother; 2022 Jul; 77(8):2265-2273. PubMed ID: 35678461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.
    Del Amo J; Polo R; Moreno S; Martínez E; Cabello A; Iribarren JA; Curran A; Macías J; Montero M; Dueñas C; Mariño AI; de la Cámara SP; Díaz A; Arribas JR; Jarrín I; Hernán MA;
    AIDS; 2022 Dec; 36(15):2171-2179. PubMed ID: 36382436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV.
    Li G; Park LS; Lodi S; Logan RW; Cartwright EJ; Aoun-Barakat L; Casas JP; Dickerman BA; Rentsch CT; Justice AC; Hernán MA
    AIDS; 2022 Oct; 36(12):1689-1696. PubMed ID: 35848570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
    Devred I; Kayembe K; Valin N; Rougier H; Shinga BW; Lambert-Niclot S; Chiarabini T; Meyohas MC; Lacombe K
    BMC Infect Dis; 2023 Sep; 23(1):578. PubMed ID: 37667182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.
    Yilmaz A; Mellgren Å; Fuchs D; Nilsson S; Blennow K; Zetterberg H; Gisslén M
    Infect Dis (Lond); 2019; 51(11-12):838-846. PubMed ID: 31556765
    [No Abstract]   [Full Text] [Related]  

  • 6. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
    Bosch B; Akpomiemie G; Chandiwana N; Sokhela S; Hill A; McCann K; Qavi A; Mirchandani M; Venter WDF
    Clin Infect Dis; 2023 Apr; 76(8):1492-1495. PubMed ID: 36519389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
    Jing C; Wei T; Ning W; Fang Z; Gang X; Xingzhi W; Guoqiang Z; Min W
    BMC Infect Dis; 2023 Jun; 23(1):396. PubMed ID: 37308847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
    Sun L; He Y; Xu L; Zhao F; Zhou Y; Zhang L; Peng Q; Zhang H; Zhang Q; Cao T; Song Y; Wang S; Rao M; Jia X; Liu X; Zhou J; Ju B; Wang H; Liu J
    J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S8-S15. PubMed ID: 36094509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
    Chetty T; Thorne C; Coutsoudis A
    PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
    Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
    HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in blood lipid levels and influencing factors among treatment-naïve adult male HIV/AIDS patients following BIC/FTC/TAF vs . 3TC+EFV+TDF.
    Wang X; Liu A; Li Z; Zhang H; Wu RE; Shao Y; Li J; Ye J; Liu W; Sun L
    Chin Med J (Engl); 2024 Jun; 137(12):1447-1452. PubMed ID: 38816366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive Efficacy of Tenofovir/Emtricitabine Against Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre-Exposure Prophylaxis Users.
    Ayerdi O; Puerta T; Clavo P; Vera M; Ballesteros J; Fuentes ME; Estrada V; Rodríguez C; Del Romero J;
    Open Forum Infect Dis; 2020 Nov; 7(11):ofaa455. PubMed ID: 33200081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.
    Del Amo J; Polo R; Moreno S; Díaz A; Martínez E; Arribas JR; Jarrín I; Hernán MA;
    Ann Intern Med; 2020 Oct; 173(7):536-541. PubMed ID: 32589451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.
    Berenguer J; Díez C; Martín-Vicente M; Micán R; Pérez-Elías MJ; García-Fraile LJ; Vidal F; Suárez-García I; Podzamczer D; Del Romero J; Pulido F; Iribarren JA; Gutiérrez F; Poveda E; Galera C; Izquierdo R; Asensi V; Portilla J; López JC; Arribas JR; Moreno S; González-García J; Resino S; Jarrín I
    Clin Microbiol Infect; 2021 Nov; 27(11):1678-1684. PubMed ID: 34186209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.
    Flandre P; Pugliese P; Allavena C; Katlama C; Cotte L; Cheret A; Cabié A; Rey D; Chirouze C; Bani-Sadr F; Cuzin L;
    HIV Med; 2016 May; 17(5):380-4. PubMed ID: 27093565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
    Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
    N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G; Sauermilch D; Gandhi M; Starks TJ
    AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
    Floridia M; Pinnetti C; Ravizza M; Masuelli G; Personeni C; Sansone M; Degli Antoni A; Guaraldi G; Spinillo A; Tassis B; Dalzero S; Liuzzi G; Tamburrini E
    J Acquir Immune Defic Syndr; 2018 May; 78(1):99-104. PubMed ID: 29406430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.